Xylem Q4 Adj. EPS $0.99 Beats $0.96 Estimate, Sales $2.12B Beat $2.05B Estimate
Portfolio Pulse from Benzinga Newsdesk
Xylem (NYSE:XYL) reported Q4 adjusted EPS of $0.99, surpassing the $0.96 estimate, and sales of $2.12B, exceeding the $2.05B estimate. This represents a 7.61% increase in earnings and a 40.64% increase in sales from the same period last year.
February 06, 2024 | 11:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xylem reported a strong Q4 with earnings and sales surpassing estimates, indicating robust financial health and growth.
Xylem's Q4 earnings and sales not only surpassed analyst estimates but also showed significant growth compared to the same period last year. This positive performance is likely to instill investor confidence and could lead to a short-term uptick in XYL's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100